CA2772190A1 - Systems and methods for producing hyperpolarized materials and mixtures thereof - Google Patents
Systems and methods for producing hyperpolarized materials and mixtures thereof Download PDFInfo
- Publication number
- CA2772190A1 CA2772190A1 CA2772190A CA2772190A CA2772190A1 CA 2772190 A1 CA2772190 A1 CA 2772190A1 CA 2772190 A CA2772190 A CA 2772190A CA 2772190 A CA2772190 A CA 2772190A CA 2772190 A1 CA2772190 A1 CA 2772190A1
- Authority
- CA
- Canada
- Prior art keywords
- nuclei
- polarization
- hyperpolarized
- temperature
- magnetic field
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000463 material Substances 0.000 title claims abstract description 636
- 238000000034 method Methods 0.000 title claims abstract description 213
- 239000000203 mixture Substances 0.000 title claims description 42
- 238000004519 manufacturing process Methods 0.000 claims abstract description 20
- 230000010287 polarization Effects 0.000 claims description 142
- 230000005291 magnetic effect Effects 0.000 claims description 110
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 69
- 238000012546 transfer Methods 0.000 claims description 66
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 62
- 239000007789 gas Substances 0.000 claims description 46
- 239000007787 solid Substances 0.000 claims description 43
- 239000003795 chemical substances by application Substances 0.000 claims description 42
- 238000002844 melting Methods 0.000 claims description 42
- 230000008018 melting Effects 0.000 claims description 42
- 238000002156 mixing Methods 0.000 claims description 40
- 239000007788 liquid Substances 0.000 claims description 38
- 230000003247 decreasing effect Effects 0.000 claims description 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 238000005481 NMR spectroscopy Methods 0.000 claims description 26
- 238000001727 in vivo Methods 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 230000002102 hyperpolarization Effects 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 15
- 238000010792 warming Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- 239000001307 helium Substances 0.000 claims description 9
- 229910052734 helium Inorganic materials 0.000 claims description 9
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 9
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 7
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 7
- 230000005298 paramagnetic effect Effects 0.000 claims description 7
- 230000009286 beneficial effect Effects 0.000 claims description 6
- 239000000084 colloidal system Substances 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 235000011089 carbon dioxide Nutrition 0.000 claims description 4
- 229940107700 pyruvic acid Drugs 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 230000031018 biological processes and functions Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 description 43
- 239000008188 pellet Substances 0.000 description 38
- 239000002243 precursor Substances 0.000 description 21
- 229960000583 acetic acid Drugs 0.000 description 20
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 19
- 239000001632 sodium acetate Substances 0.000 description 19
- 235000017281 sodium acetate Nutrition 0.000 description 19
- OHSJPLSEQNCRLW-UHFFFAOYSA-N triphenylmethyl radical Chemical compound C1=CC=CC=C1[C](C=1C=CC=CC=1)C1=CC=CC=C1 OHSJPLSEQNCRLW-UHFFFAOYSA-N 0.000 description 15
- 230000005641 tunneling Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940054269 sodium pyruvate Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- UQVKZNNCIHJZLS-UHFFFAOYSA-N PhIP Chemical compound C1=C2N(C)C(N)=NC2=NC=C1C1=CC=CC=C1 UQVKZNNCIHJZLS-UHFFFAOYSA-N 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000003574 free electron Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000005415 magnetization Effects 0.000 description 3
- 230000028161 membrane depolarization Effects 0.000 description 3
- 238000005453 pelletization Methods 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- 239000004078 cryogenic material Substances 0.000 description 2
- 230000002999 depolarising effect Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical group [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000446304 Vela Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- QTBSBXVTEAMEQO-GUEYOVJQSA-N acetic acid-d4 Chemical compound [2H]OC(=O)C([2H])([2H])[2H] QTBSBXVTEAMEQO-GUEYOVJQSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000004964 aerogel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- -1 methyl carbon Chemical group 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229910000595 mu-metal Inorganic materials 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/282—Means specially adapted for hyperpolarisation or for hyperpolarised contrast agents, e.g. for the generation of hyperpolarised gases using optical pumping cells, for storing hyperpolarised contrast agents or for the determination of the polarisation of a hyperpolarised contrast agent
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23864709P | 2009-08-31 | 2009-08-31 | |
| US61/238,647 | 2009-08-31 | ||
| PCT/US2010/047310 WO2011026103A2 (en) | 2009-08-31 | 2010-08-31 | Systems and methods for producing hyperpolarized materials and mixtures thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2772190A1 true CA2772190A1 (en) | 2011-03-03 |
Family
ID=43628703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2772190A Abandoned CA2772190A1 (en) | 2009-08-31 | 2010-08-31 | Systems and methods for producing hyperpolarized materials and mixtures thereof |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2473198A4 (enExample) |
| JP (1) | JP5792726B2 (enExample) |
| KR (1) | KR20120101339A (enExample) |
| CN (1) | CN102753201A (enExample) |
| AU (1) | AU2010286413B2 (enExample) |
| CA (1) | CA2772190A1 (enExample) |
| IN (1) | IN2012DN02418A (enExample) |
| SG (1) | SG178927A1 (enExample) |
| WO (1) | WO2011026103A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101095943B1 (ko) | 2006-02-21 | 2011-12-19 | 밀리켈빈 테크놀로지스 엘엘씨 | 과분극화 방법, 시스템 및 조성물 |
| US8703102B2 (en) | 2008-04-04 | 2014-04-22 | Millikelvin Technologies Llc | Systems and methods for producing hyperpolarized materials and mixtures thereof |
| GB2498181A (en) | 2011-12-29 | 2013-07-10 | Bruker Biospin Gmbh | Device and method for rapid dynamic nuclear polarisation |
| US9329246B2 (en) | 2012-10-03 | 2016-05-03 | Bruker Biospin Ag | Method for hyperpolarization transfer in the liquid state |
| US9404984B2 (en) | 2012-11-06 | 2016-08-02 | Bruker Uk Limited | Method of hyperpolarization applying brute force using particulate acceleration agents |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545396A (en) * | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
| US5617859A (en) | 1995-10-02 | 1997-04-08 | General Electric Company | Apparatus and methods for magnetic resonance (MR) imaging of cavities using fluids polarized at low temperatures |
| US5809801A (en) * | 1996-03-29 | 1998-09-22 | The Trustees Of Princeton University | Cryogenic accumulator for spin-polarized xenon-129 |
| RU2186405C2 (ru) | 1996-03-29 | 2002-07-27 | Лоренс Беркли Нэшнл Лэборэтори | Усиление ядерного магнитного резонанса (ямр) и магниторезонансной визуализации (мрв) в присутствии гиперполяризованных благородных газов |
| CN1224502A (zh) * | 1996-03-29 | 1999-07-28 | 劳伦斯·伯克利国家实验室 | 利用超极化惰性气体对于核磁共振和磁共振成象质量的提高 |
| GB9614139D0 (en) | 1996-07-05 | 1996-09-04 | Nycomed Imaging As | Method |
| EP0951650B1 (en) * | 1997-01-08 | 2003-12-10 | Amersham Health AS | Method of magnetic resonance imaging |
| CA2290808A1 (en) * | 1997-06-19 | 1998-12-23 | Jan Henrik Ardenkjaer-Larsen | Overhauser magnetic resonance imaging (ormi) method comprising ex vivo polarization of a magnetic resonance (mr) imaging agent |
| KR100600670B1 (ko) | 1997-11-12 | 2006-07-13 | 지이 헬스케어 에이에스 | 파라수소 표지된 작용물질 및 자기공명영상에서의 그의 용도 |
| US6278893B1 (en) * | 1998-01-05 | 2001-08-21 | Nycomed Imaging As | Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent |
| GB0001727D0 (en) | 2000-01-25 | 2000-03-15 | Oxford Instr Uk Ltd | Hyperpolarization of a noble gas |
| AU1403902A (en) | 2000-11-03 | 2002-05-15 | Amersham Health As | Methods and devices for polarised nmr samples |
| DK1330659T3 (da) * | 2000-11-03 | 2006-12-18 | Amersham Health As | Fremgangsmåde og indretning til oplösning af hyperpolariseret, fast materiale til NMR-analyser |
| NO20025738D0 (no) * | 2002-11-29 | 2002-11-29 | Amersham Health As | Metode |
| DE102004002639A1 (de) * | 2004-01-19 | 2005-09-15 | Forschungszentrum Jülich GmbH | Verfahren zur Anreicherung von hyperpolarisierten Atomkernen und Vorrichtung zur Durchführung des Verfahrens |
| GB0501346D0 (en) * | 2005-01-21 | 2005-03-02 | Oxford Instr Molecular Biotool | Method of carrying out dynamic nuclear polarization |
| FR2881226B1 (fr) * | 2005-01-27 | 2007-04-27 | Commissariat Energie Atomique | Accroissement de la polarisation des spins nucleaires d'une molecule via un transfert de polarisation de type hartmann-hahn utilisant le champ dipolaire moyen cree par une source |
| GB0514303D0 (en) * | 2005-07-12 | 2005-08-17 | Oxford Instr Molecular Biotool | Magnet assembly |
| KR101095943B1 (ko) * | 2006-02-21 | 2011-12-19 | 밀리켈빈 테크놀로지스 엘엘씨 | 과분극화 방법, 시스템 및 조성물 |
| NL2000122C2 (nl) * | 2006-07-03 | 2008-01-07 | Vialle Alternative Fuel System | Bufferhouder. |
| US7631507B2 (en) * | 2006-11-02 | 2009-12-15 | General Electric Company | Methods and devices for polarized samples for use in MRI |
| US20080242974A1 (en) * | 2007-04-02 | 2008-10-02 | Urbahn John A | Method and apparatus to hyperpolarize materials for enhanced mr techniques |
| US7519492B2 (en) * | 2007-05-02 | 2009-04-14 | General Electric Company | Apparatus and method for fully automated closed system quality control of a substance |
-
2010
- 2010-08-31 AU AU2010286413A patent/AU2010286413B2/en not_active Ceased
- 2010-08-31 IN IN2418DEN2012 patent/IN2012DN02418A/en unknown
- 2010-08-31 EP EP10812752.3A patent/EP2473198A4/en not_active Withdrawn
- 2010-08-31 WO PCT/US2010/047310 patent/WO2011026103A2/en not_active Ceased
- 2010-08-31 CN CN2010800471391A patent/CN102753201A/zh active Pending
- 2010-08-31 CA CA2772190A patent/CA2772190A1/en not_active Abandoned
- 2010-08-31 SG SG2012014379A patent/SG178927A1/en unknown
- 2010-08-31 JP JP2012527097A patent/JP5792726B2/ja not_active Expired - Fee Related
- 2010-08-31 KR KR1020127008209A patent/KR20120101339A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| SG178927A1 (en) | 2012-04-27 |
| EP2473198A4 (en) | 2015-06-24 |
| CN102753201A (zh) | 2012-10-24 |
| AU2010286413B2 (en) | 2014-11-20 |
| AU2010286413A1 (en) | 2012-04-05 |
| WO2011026103A2 (en) | 2011-03-03 |
| IN2012DN02418A (enExample) | 2015-08-21 |
| JP2013503021A (ja) | 2013-01-31 |
| WO2011026103A3 (en) | 2011-07-21 |
| JP5792726B2 (ja) | 2015-10-14 |
| KR20120101339A (ko) | 2012-09-13 |
| EP2473198A2 (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8703102B2 (en) | Systems and methods for producing hyperpolarized materials and mixtures thereof | |
| JP4764548B2 (ja) | 磁気共鳴調査方法 | |
| CA2643306C (en) | Hyperpolarization methods, systems and compositions | |
| US5785953A (en) | Magnetic resonance imaging using hyperpolarized noble gases | |
| US20140223923A1 (en) | Systems and methods for producing hyperpolarized materials and mixtures thereof | |
| US6125654A (en) | Bulk production and usage of hyperpolarized 129 Xenon | |
| US8825132B2 (en) | Field cycling method for magnetic resonance | |
| AU2010286413B2 (en) | Systems and methods for producing hyperpolarized materials and mixtures thereof | |
| Hirsch et al. | Transport and imaging of brute-force 13C hyperpolarization | |
| US20130168576A1 (en) | Device and method for rapid dynamic nuclear polarization | |
| US20160274043A1 (en) | Enhanced 13C NMR by Thermal Mixing with Hyperpolarized 129XE | |
| US20110050228A1 (en) | agent for transporting nuclear spin order and for magnetic resonance imaging | |
| EP2917749B1 (en) | Method of hyperpolarization applying brute force using particulate acceleration agents | |
| JP4420224B2 (ja) | 過分極１２９Ｘｅの製造法 | |
| CA2720333C (en) | Manufacture, transport and delivery of material containing highly polarized nuclei | |
| JP5117375B2 (ja) | Ｌｉ及び別の核の過偏極 | |
| US9658300B1 (en) | Method and apparatus for preparation of spin polarized reagents | |
| van den Brandt et al. | Dynamic nuclear polarization–from polarized targets to metabolic imaging | |
| Charlaftis | Dynamic Nuclear Polarization of Beta-Cyclodextrin Derivatives | |
| Smith et al. | Non-resonant SABRE provides a new and versatile hyperpolarization approach for magnetic resonance | |
| Khashami | Hyperpolarized MRI technique and its application in medical science | |
| O'Neill | Brute force polarisation of xenon-129 | |
| AU2016204108A1 (en) | Hyperpolarization Methods, Systems and Compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150731 |
|
| FZDE | Discontinued |
Effective date: 20180228 |